tezampanel Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Tezampanel is a drug originally developed by Eli Lilly which acts as a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family, with selectivity for the GluR5 subtype of the kainate receptor. It has neuroprotective and anticonvulsant properties, the former of which may, at least in part, occur via blockade of calcium uptake into neurons.   Wikipedia

Chemistry

  • SMILES: O.OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1
  • InChIKey: LNDYQNTTYXLTNH-RTBBDAMFSA-N
  • Mol. Mass: 297.36
  • ALogP: 0.61
  • ChEMBL Molecules:
    tezampanel  
    tezampanel  
More Chemistry

Pharmacology

Alternative names

(3s,4ar,6r,8ar)-6-(2-(1(2)h-tetrazole-5yl)ethyl)decahydroisoquinoline-3carboxylic acid | 6-(2-(1h-tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid | ly 215490 | ly-215490 | ly293558 | ly 293558 | ly-293558 | ly 326325 | ly-326325 | ngx424 | tezampanel

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Migraine Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue